Hypertension Clinical Trial Landscape

The hypertension clinical trial landscape in 2026

Hypertension is one of the most prevalent conditions in medicine, affecting roughly 1.3 billion people worldwide, yet its drug development pipeline has historically been considered mature and largely exhausted. That perception is changing. The emergence of aldosterone synthase inhibitors (lorundrostat, baxdrostat) targeting the adrenal mineralocorticoid pathway, the successful re-approval of catheter-based renal denervation, and the entry of RNA-based therapeutics into the cardiovascular space have opened a wave of clinical trial activity targeting resistant hypertension and patients inadequately controlled on existing therapies. As of 2026, the NIH/NHLBI and AstraZeneca are among the most active sponsors in our database, alongside a range of academic cardiovascular centers running combination strategy trials.

The key commercial opportunity is resistant hypertension, defined as blood pressure above goal despite three or more antihypertensive medications including a diuretic, or requiring four or more medications to achieve control. This population is estimated at 10–15% of all hypertensive patients, or 12–20 million people in the United States alone. Resistant hypertension carries disproportionately high cardiovascular event risk and is enriched for secondary causes including primary aldosteronism, obstructive sleep apnea, and chronic kidney disease. The pipeline targeting resistant hypertension with novel mechanisms (rather than yet another ARB or CCB) is active and commercially significant.

A parallel development is the deepening integration of hypertension and CKD trials. Sparsentan, a dual endothelin/angiotensin receptor antagonist, received FDA approval for IgA nephropathy in 2023 and is being evaluated in resistant HTN with CKD. Sacubitril/valsartan (Entresto), established in heart failure with reduced ejection fraction, is being evaluated in HTN populations. The convergence of cardiorenal science is producing a set of trials that pipeline teams must monitor across both disease areas.

• Aldosterone synthase inhibitors, lorundrostat (AstraZeneca, Phase 3 TARGET HTN), baxdrostat (AstraZeneca/KBP Biosciences), highly selective CYP11B2 inhibitors
• Renal denervation. Medtronic Symplicity Spyral catheter (FDA approved 2023), endovascular ultrasound (ReCor Paradise system, FDA approved 2023), ongoing real-world registries
• Endothelin antagonists, sparsentan (for resistant HTN/CKD/IgAN), aprocitentan (Tryvio, approved 2024 for resistant HTN)
• ARNi combinations, sacubitril/valsartan in hypertension populations, combinations with newer agents
• RNA-based therapeutics, zilebesiran (Alnylam, Phase 2/3 KARDIA trials, siRNA targeting angiotensinogen), inclisiran indirect BP effects in high-risk CVD
• Renal artery stenosis interventions, stenting vs. medical therapy in atherosclerotic RAS, fibromuscular dysplasia
• Mineralocorticoid receptor antagonists (MRAs): finerenone (Kerendia, approved in DKD/HF) being explored in resistant HTN with renal protection endpoint

What we monitor for hypertension

Our system pulls from the ClinicalTrials.gov API every day. For a hypertension watch profile, you can configure a saved search for:

• Keywords: "hypertension," "resistant hypertension," "treatment-resistant hypertension," "renal denervation," "aldosterone synthase," "lorundrostat," "baxdrostat," "sparsentan," "aprocitentan," "zilebesiran," "sacubitril/valsartan HTN," "primary aldosteronism"
• Phase filters: Phase 1 (novel mechanisms, first-in-human RNA therapeutics), Phase 2 (proof-of-concept, ambulatory BP endpoints), Phase 3 (pivotal outcomes and registration trials)
• Sponsor type: large pharma (AstraZeneca, Alnylam, Novartis), device companies (Medtronic, ReCor Medical), NIH/NHLBI academic networks
• Study status: not yet recruiting, recruiting, active not recruiting
• Sub-population: resistant hypertension, primary aldosteronism, hypertension with CKD, hypertension with heart failure, nocturnal/masked hypertension

Device-based hypertension treatment: renal denervation's second chance

Renal denervation had one of the most dramatic falls from grace in modern cardiology. The original SYMPLICITY HTN-3 trial, published in 2014, showed no significant blood pressure reduction compared to sham procedure, a result that nearly ended the field. Years of retrospective analysis revealed the likely culprit: inadequate sympathetic nerve ablation due to poor catheter contact in the circumferential renal artery wall, compounding of the results by medication non-adherence, and flawed trial design that failed to standardize background therapy. A generation of redesigned catheters and more rigorous trial protocols followed.

The SPYRAL HTN-ON MED trial, using Medtronic's redesigned Symplicity Spyral spiral catheter with four electrodes providing 360-degree coverage, showed significant 24-hour ambulatory systolic blood pressure reductions at 6 months in patients on stable antihypertensive medication. The FDA approved the Symplicity Spyral system in November 2023, and ReCor Medical's Paradise endovascular ultrasound renal denervation system received FDA approval shortly thereafter. These approvals have re-opened clinical trial activity: real-world effectiveness registries, combination therapy trials (denervation plus aldosterone synthase inhibitor), and pediatric/young adult feasibility studies are all appearing on ClinicalTrials.gov.

For cardiovascular pharma BD teams and device companies, the re-emergence of renal denervation as an FDA-approved option creates important combination strategy questions. A patient undergoing denervation who also receives an aldosterone synthase inhibitor may achieve additive reductions through orthogonal mechanisms (sympathetic nervous system plus renin-angiotensin-aldosterone system). Trials exploring these combinations, and identifying which patients respond best to device, drug, or combined approaches, will be a significant source of clinical registrations over the next several years.

Who uses hypertension trial monitoring

• Cardiovascular pharma and biotech BD teams: tracking aldosterone synthase inhibitors, RNA-based antihypertensives, endothelin antagonists, and cardiorenal combination programs across Phase 2 and 3
• Cardiologist and nephrologist researchers: monitoring industry programs for investigator-site opportunities, particularly in resistant HTN and CKD/HTN overlap populations
• Interventional cardiology device companies: tracking competitive renal denervation programs, real-world registries, and indication expansion trials
• Cardiovascular CROs: identifying new sponsor relationships and site qualification opportunities for complex ambulatory blood pressure and outcomes-based hypertension protocols
• Cardiovascular investors: monitoring Phase 2/3 data catalysts and new program registrations in the now-active resistant hypertension space